|AHFS/Drugs.com||International Drug Names|
|Chemical and physical data|
|Molar mass||509.59 g/mol|
|3D model (JSmol)|
|(what is this?)|
Mode of action
The drug acts as an ultra-short-acting β1-selective blocking agent. It is rapidly hydrolyzed to an inactive form by both carboxylesterase in the liver and pseudocholinesterase[disambiguation needed] in the plasma, resulting in an elimination half-life of about 4 minutes. 
The drug was developed by modifying the chemical structure of esmolol to produce a compound with a higher rate of cardioselectivity and a greater potency without increasing its duration of action. It is sold as landiolol hydrochloride. 
- Yamamoto, Natsuko; et al. (2017). "Heart Rate Response to Intravenous Landiolol during Propofol Anesthesia". CIRCULATION CONTROL. 38 (1): 35–39. ISSN 0389-1844. doi:10.11312/ccm.38.35. Retrieved May 10, 2017.
- Yoshiya I (December 1998). "[Landiolol hydrochloride, a new sympathetic beta blocker]". Masui (in Japanese). 47 Suppl: S126–32. PMID 9921175.
- Ogata J, Okamoto T, Minami K (2003). "Landiolol for the treatment of tachyarrhythmia associated with atrial fibrillation". Can J Anaesth. 50 (7): 753. PMID 12944459. doi:10.1007/BF03018726.
|This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.|